Introduction
============

Cariprazine, a drug under development for schizophrenia and bipolar disorder, is a dopamine D~3~ and D~2~ receptor (D~3~R and D~2~R, respectively) partial agonist with preferential binding to D~3~R [@b29]. Dopaminergic activity has been associated with the regulation of locomotion, reward, emotion, and affect, while dysregulation of this system has been implicated in both bipolar disorder [@b13] and schizophrenia [@b23].

Classical dopaminergic physiological functions are mediated through five receptors with seven-transmembrane spanning G protein-coupled regions, which either enhance (D~1~ and D~5~ receptors) or inhibit (D~2~, D~3~, D~4~) cellular cyclic AMP (cAMP) production. The inhibitory pathway receptors can also modulate calcium and potassium channels through the activity of G protein *βγ* subunits ([@b22]; [@b44]; [@b3]).

In addition, several lines of evidence suggest that the D~2~R (and to a lesser extent the D~3~R) can also act through a G protein-independent pathway to increase glycogen synthase kinase-3 (GSK-3) activity, *via* a complex consisting of *β*-arrestin 2, protein kinase B (Akt), and protein phosphatase 2A (PP2A) [@b4],[@b5],[@b7]. In this pathway, PP2A dephosphorylates and deactivates the kinase Akt, thereby enabling the subsequent dephosphorylation and activation of GSK-3 (for a review, see [@b4]). It has been hypothesized that hyperactivation of GSK-3 is involved in both bipolar disorder [@b32] and schizophrenia [@b30].

In support of this hypothesis, mice that overexpress the GSK-3*β* subunit have a phenotype of hyperactivity similar to mice treated with amphetamine, and behavior akin to mania [@b39]. Moreover, mice overexpressing D~2~R in the striatal complex (presumably leading to an increased dopaminergic state) display cognitive and working memory deficits characteristic of mania and psychosis [@b42]. Lithium, a mood stabilizer commonly used in bipolar disorder, has been shown to inhibit GSK-3 both directly and through an indirect mechanism that destabilizes this D~2~R-mediated *β*-arrestin 2/Akt/GSK-3 signaling complex ([@b6]; [@b38]).

The GSK-3 signaling pathway has also been implicated in the actions of antidepressants and antipsychotics [@b33],[@b34]. While antipsychotics have diverse and complex pharmacological actions, activity at dopamine D~2~R is believed to underlie their clinical efficacy [@b19]. Interestingly, although individual antipsychotics show differential effects on D~2~R-mediated G protein activation (ranging from inverse to partial agonism to antagonism), all antipsychotics display a common biased antagonism for the D~2~R/â-arrestin 2 interaction [@b35].

As a D~3~R and D~2~R partial agonist, cariprazine may activate/inhibit both subtypes of dopamine receptors depending on the actual dopaminergic tone [@b29]. Although the role of D~3~R in the *β*-arrestin 2/Akt/GSK-3 signaling pathway has not been extensively studied, preliminary studies with D~3~R knockout mice suggest that the D~3~R plays a role in regulating and enhancing the sensitivity of the D~2~R [@b5]. To investigate the effects of cariprazine on D~3~R/D~2~R-related signaling, we compared its activity with that of haloperidol (a typical antipsychotic) and aripiprazole (a dopamine D~2~ partial agonist atypical antipsychotic) in two in vitro assays: a G protein-mediated cAMP inhibition assay and an assay to measure the interaction between the D~2~R and *β*-arrestin 2. In addition, we tested the effect of cariprazine in an animal model of mania, inducing mania-like behavior via injection with ouabain, a potent inhibitor of the Na^+^/K^+^ transmembrane ATPase. Intracerebroventricular (i.c.v.) ouabain injection is among the best characterized models of mania, and is the only available model of bipolar disorder that adequately fulfills all major criteria required of an animal model [@b21]. Ouabain-injected rats have been shown to be sensitive to lithium and other antimanic agents such as carbamazepine and haloperidol (but not olanzapine) [@b21]. Additionally, the model has been used with novel agents such as memantine, which is predicted by the model to have antimanic efficacy [@b18]. Ouabain can also alter the phosphorylation state of Akt in some cell lines in vitro ([@b26],[@b27]; [@b41]), as well as in vivo in rats, on the same time scale as its manic effects [@b47], suggesting that GSK-3 signaling may be involved in this model system as well. More recently, a knockout mouse model, in which the animals are hemideficient for the alpha3 subunit of the Na^+^/K^+^ ATPase, has been shown to induce lithium-normalized manic-like behavior [@b28]. Nonetheless, animal models based on the single alterations that attempt to mimic a complex human illness such as bipolar disorder, need to be viewed with some caution.

Materials and Methods
=====================

Drugs investigated
------------------

Cariprazine and aripiprazole were provided by Forest Research Institute (Forest Laboratories Inc., New York, NY); haloperidol and quinpirole were purchased from Sigma-Aldrich (St. Louis, MO).

In vitro assays
---------------

### Cell culture and transient transfections

Human embryonic kidney HEK-293T cells (ATCC, Manassas, VA), were maintained in Dulbecco\'s Modification of Eagle\'s Medium supplemented with 10% fetal bovine serum (FBS; Sigma-Aldrich), 0.05 mg/mL of Gentamicin, and 2 mmol/L glutamine, in a 5% CO~2~ incubator. Cells were seeded at a density of 3 × 10^6^ cells per 100 mm dishes, or at 500,000 cells/well in six-well plates, and then cultured for 24 h and transfected using calcium phosphate. Twenty-four hours post transfection, the cells were divided into 96-well clear bottom plates (Corning, Lowell, MA) in phenol-free Minimum Essential Medium (Gibco, Grand Island, NY) supplemented with 2% FBS, 2 mmol/L [l]{.smallcaps}-glutamine, and 0.05 mg/mL gentamicin. Assays were conducted 24 h after plating cells onto the 96-well plates.

### Measurement of cAMP production

HEK-293T cells were transfected with the GloSensor™ cAMP construct (Promega, Madison, WI) and mouse D~2~R-long form (mD~2L~R) DNA [@b35]. On the day of the experiment, the cells were washed in Hank\'s Balanced Salt Solution (HBSS; Gibco, Grand Island, NY); then 25 *μ*L of 25 mmol/L luciferin (Gold Biotechnology, St. Louis, MO) in HBSS was added to each well and incubated in the dark at room temperature for 2 h. Following incubation, the luciferin solution was aspirated and 80 *μ*L HBSS was added, and dose--response curves were generated for quinpirole, aripiprazole, and cariprazine. Five minutes after the addition of each drug, isoproterenol (10^−7^ mol/L) was added to induce cAMP production for an additional five minutes. Luminescence generated from the GloSensor™ construct was measured with a Mithras LB940 Multimode Reader, using MikroWin 2000 software (Berthold Technologies, Oak Ridge, TN). All curves generated were normalized to the maximal response of isoproterenol, to control for expression differences between experiments.

### Measurement of the interaction between the D~2~R and *β*-arrestin-2

Bioluminescence resonance energy transfer (BRET) assays were performed as described in [@b35], with minor modifications. Briefly, mD~2L~R DNA was fused with that of *Renilla* luciferase (RLuc; the BRET donor, emission wavelength of 465--505 nm), and mouse *β*-arrestin-2 (m*β*-arrestin-2) DNA was fused with that of enhanced yellow fluorescent protein (EYFP; the BRET acceptor, emission wavelength of 515--555 nm); the resulting mD~2L~R-RLuc and m*β*-arrestin-2-EYFP transcripts were transfected into HEK-293T cells and cultured as described above. The ratio of BRET donor and acceptor was carefully controlled and experiments carried out as previously described [@b35]. Briefly, mD~2L~R-RLuc (0.2 *μ*g DNA/100 mm dish) and 10 *μ*g DNA/dish of m*β*-arrestin-2 EYFP were transfected using calcium phosphate. Between experiments the mD~2L~R-RLuc expression as confirmed by RLuc emission did not vary more than 10%. Twenty-four hours after calcium phosphate transfection, the cells were detached and plated in phenol red-free medium containing 2% of FBS, 0.05 mg/mL of Gentamicin and 2 mmol/L glutamine in 96-well microplates (White OptiPlate, Perkin Elmer, Waltham, MA) at a density of 100,000 cells per well. After an additional 24 h, the medium was removed and replaced by phosphate buffer saline (PBS) containing calcium and magnesium and 0.003% (w/v) ascorbic acid before initiating the assay.

The BRET assay was initiated by adding 10 *μ*L of the cell-permeable substrate specific for *Renilla* luciferase, coelenterazine h (Promega, Madison, WI), at a final concentration of 5 *μ*mol/L. After 5 min, cariprazine, aripiprazole, and haloperidol, were added across seven decades of concentration (see [Fig. 2](#fig02){ref-type="fig"}) and assessed 5 min later. In antagonist assays the concentrations of cariprazine, aripiprazole, and haloperidol were added 1 min after the addition of the coelenterazine h substrate, quinpirole (final concentration 1 *μ*mol/L) was added at 5 min, and the plate was assayed 10 min after the substrate addition. The ratio of EYFP emission to RLuc emission was measured using a Mithras LB940 with Mikrowin 2000 software. The BRET ratios derived were normalized to the maximal quinpirole response on mD~2L~R-RLuc.

### Data analysis

Data analysis for cAMP assays was performed on curves normalized to the inhibition of isoproterenol-induced response, while BRET values were normalized to the maximal response of the full agonist, quinpirole. This allows for the most facile way to portray the partial agonist activity present for cariprazine and aripiprazole at the cAMP assay. For agonist assays, the dose--response curves were calculated using GraphPad Prism 5 using the nonlinear regression curve fit for the function *Y* = Bottom +(Top-Bottom)/{1 + 10\^(\[LogEC~50~-*X*\[)}, which is referred to as "log\[agonist\[ versus response" in the software. The errors present in the table were calculated from the curve fit. For antagonist assays, the dose--response curves were calculated using the nonlinear regression curve fit for the function *Y* = Bottom + (Top-Bottom)/{1 + 10\^(\[*X*-LogIC~50~\[)}, which is referred to as "log\[inhibitor\[ versus response" in the software. The IC~50~ values were used to calculate the K~B~ values for haloperidol, aripiprazole, and cariprazine using the equation, *K*~B~ = IC~50~/{(2 + (\[A\[/EC~50~)^*n*^)^1/*n*^ − 1} where IC~50~ was calculated from the experimental curves, \[A\[ = concentration of quinpirole used, EC~50~ = the EC~50~ of quinpirole for each functional assay, and *n* = the hill coefficient (which had a value of 1 for BRET experiments).

Behavioral testing
------------------

### Animals

All animal procedures were approved by the University of Louisville institutional animal studies committee. Adult male Sprague--Dawley rats (150--300 g; Harlan, Indianapolis, IN) were housed individually at 24--26°C in a 12 h:12 h, light:dark cycle; food and water were provided ad libitum. The animals were allowed to acclimate to the animal facility for 4--5 days after shipping. Cannulae were surgically implanted (i.c.v.) according to methodology reported previously [@b14]. During the conduct of the study an imbalance in sample size developed, with the number of rats per treatment group ranging from 3 to 8. All statistical analyses are for the final number of rats in each group. Throughout the studies, the animals were individually caged. Experiments on animals were conducted according to the Guide for the Care and Use of Laboratory Animals, as adopted and promulgated by the U.S. National Institutes of Health.

### Ouabain-induced mania

Mania-like behavior was induced by single i.c.v. injection of 5 *μ*L of 1 mmol/L ouabain (Sigma, St. Louis, MO) dissolved in artificial cerebrospinal fluid (aCSF) 4 days after the cannulation surgery. The aCSF consisted of 124 mmol/L NaCl, 5 mmol/L KCl, 3.7 mmol/L MgSO~4~, 23 mmol/L NaHCO~3~, and 0.75 mmol/L NaH~2~PO~4~, pH 7.4 [@b10]. Open field activity was examined immediately after i.c.v. injection of ouabain and also at 7 days post injection.

Cariprazine was dissolved in 0.9% saline and administered at 0.06, 0.25, 0.5, and 1.0 mg/kg via intraperitoneal (i.p.) injection 1 h before i.c.v. injection of ouabain and daily thereafter for 7 days. Open field activity was assessed immediately following the i.c.v. injection and again after 7 days (the activity was noted 10--14 h after the last i.p. injection of cariprazine).

"Acute" lithium was administered via i.p. injection (6.75 mEq/kg) 1 h before i.c.v. injection of ouabain; whereas maintenance doses were added to rat chow (Harlan Teklad, Madison, WI), at 2.4 g/kg of food, for 7 days. This lithium dose is known to achieve behaviorally quantifiable levels of 1.01 ± 0.18 mmol/L in the rats [@b15]. Open field activity was examined 1 h and 18 h after lithium administration, and again on day 7. After an i.p. injection, lithium concentrations reach a maximum serum level by 0.5 h and maximum brain levels by 8 h [@b36]. Control animals received an i.c.v. injection of 5 *μ*L aCSF and an i.p. injection of saline, of the same volume as cariprazine-treated animals.

Behavioral testing was performed in an open arena (86 × 86 cm) that was evenly divided into 16 squares (21.5 × 21.5 cm, marked on the floor). Open field activity was defined as the number of squares traversed in 30 min, assessed by a trained observer. Baseline open field activity was assessed before cannulae implantation, 4 days after shipping of the animal, to allow for acclimation to the testing arena.

### Data analysis

The behavioral data were evaluated to determine whether acute or long-term cariprazine administration is capable of normalizing ouabain-induced hyperactivity. Raw data from each treatment group were evaluated and filtered, such that only data falling within the 95% confidence interval of the sample (assuming normal distribution) were retained for further analysis. Statistical evaluation (performed separately for the acute and the long-term experiments) utilized two-factorial analysis of variance (ANOVA), with i.p. drug treatment (including the Li-treated group) and ouabain treatment as between-groups factors. Student--Newman--Keuls test was used for post hoc analyses. Data are reported as means with standard error of mean (SEM).

Results
=======

D~2~R-dependent effects on cAMP production and â-arrestin 2 interaction
-----------------------------------------------------------------------

To compare the effects of cariprazine with that of other atypical and typical antipsychotics, we assayed the effects of cariprazine, aripiprazole, and haloperidol in cell culture on G protein-mediated cAMP production and *β*-arrestin 2 recruitment.

Cariprazine was over sixfold more potent (EC~50~ = 1.4 nmol/L) than aripiprazole (EC~50~ = 9.2 nmol/L) in inhibiting isoproterenol-induced cAMP production in HEK-293 cells; however, both compounds displayed similar maximum effect (∼75% of efficacy, in comparison with the full D~2~R agonist quinpirole) (Fig.[1A](#fig01){ref-type="fig"}; Table[1](#tbl1){ref-type="table"}). In this assay, haloperidol demonstrated no intrinsic activity and instead behaved as a potent D~2~R antagonist (data not shown; [@b35]).

![D~2~R agonist effects on cAMP production and â-arrestin recruitment. (A) pharmacological profile of D~2~R-mediated inhibition of G protein-dependent cAMP production by cariprazine, compared with the atypical antipsychotic aripiprazole and the selective D~2~R/D~3~R agonist quinpirole. (B) Lack of activity of haloperidol, a full antagonist, compared to aripiprazole and cariprazine, which are very weak partial agonists for â-arrestin 2 recruitment. Results shown are the average of 3--4 different experiments, each run in triplicates.](prp20003-e00073-f1){#fig01}

###### 

Activity of cariprazine in G protein and B-arrestin-2 signaling pathways

  Drug               G protein        *β*−arrestin-2                                                   
  ------------------ ---------------- ---------------- ---------------- ------------- ---------------- -----------
  Quinpirole         100 ± 2.2        1.1 ± 0.1        95.1 ± 4.7       109.1 ± 1.3   Not determined   
  Haloperidol        Not determined   Not determined   101.2 ± 4.3      1.3 ± 0.5                      
  Aripiprazole       77.7 ± 4.2       9.2 ± 0.1        Not determined   77.6 ± 5.1    8.7 ± 6.0        
  Cariprazine        77.4 ± 2.8       1.4 ± 0.1        13.9 ± 1.2       0.2 ± 2.9     80.4 ± 2.6       1.6 ± 1.9
  Cariprazine/GRK2   Not determined   38.4 ± 2.3       0.5 ± 2.1        62.9 ± 2.9    11.1 ± 0.2       

Results show mean ± standard error (SE). Cariprazine/GRK2 denotes evaluation of cariprazine in cells overexpressing GRK2.

The same compounds were tested for their ability to promote the interaction of the mouse D~2~R with *β*-arrestin 2 using a BRET assay. While haloperidol showed no agonist activity, both aripiprazole and cariprazine showed very weak activity (∼10%) compared with the full agonist quinpirole in this BRET assay (Fig.[1B](#fig01){ref-type="fig"}; Table[1](#tbl1){ref-type="table"}). When tested for their ability to antagonize the effect of quinpirole in this assay, all three agents inhibited the ability of quinpirole to promote interactions between D~2~R and *β*-arrestin 2; cariprazine (*K*~B~ = 1.6 nmol/L) was as potent as the classical D~2~R antagonist haloperidol (*K*~B~ = 1.3 nmol/L) and more potent than aripiprazole (*K*~B~ = 8.7 nmol/L) (Table[1](#tbl1){ref-type="table"}). Potentially reflecting their ability to act as D~2~R partial agonists and promote D~2~R/*β*-arrestin-2 interaction, the maximal antagonist activity of cariprazine and aripiprazole was significantly less than that of haloperidol) (Fig.[2A](#fig02){ref-type="fig"}). In order to more fully characterize the ability of cariprazine to function both as a weak partial agonist as well as an antagonist for the recruitment of â-arrestin-2 to D2R (Fig.[2B](#fig02){ref-type="fig"}), we performed assays with GRK2 overexpression, several folds over the endogenous levels (data not shown; Fig[2C](#fig02){ref-type="fig"}). Receptor kinase overexpression enhances D~2~R phosphorylation and enhances the efficacy for agonists. Figure[2C](#fig02){ref-type="fig"} clearly shows that cariprazine is capable of functioning as a stronger partial agonist in the presence of overexpressed kinase, however, the compound does maintain a potent antagonist effect (Table[1](#tbl1){ref-type="table"}). Under those conditions as would be expected, the extent of the antagonist effect of cariprazine is reduced to match the level of partial agonist activity of the compound.

![*β*-arrestin 2 antagonism. (A) Inhibition of quinpirole-induced *β*-arrestin 2/D~2~R complex formation by cariprazine, aripiprazole, and haloperidol. (B) Comparison of antagonism as well as agonism of *β*-arrestin 2 recruitment induced by cariprazine under endogenous complement of GPCR kinase (GRK). (C) Comparison of antagonism and agonism of *β*-arrestin 2 recruitment induced by cariprazine with overexpression of GRK2. Results shown are expressed relative to the effects of Quinpirole at 10^−6^ mol/L and are the averages of 3--4 different experiments, each run in triplicate.](prp20003-e00073-f2){#fig02}

Effect of cariprazine in the ouabain-induced rat mania model
------------------------------------------------------------

To investigate the effects of cariprazine in an animal model of mania, we administered it to rats prior to injection with ouabain, a potent inhibitor of the Na^+^/K^+^ transmembrane ATPase. In the acute experiment cariprazine (0.06--1.0 mg/kg) or lithium was injected (i.p.) 1 h before the administration of ouabain; open field activity was assessed immediately after ouabain injection. A two-factorial ANOVA revealed a significant drug-treatment effect (*F*~5,50~ = 13.52, *P *\<* *0.001), a significant ouabain effect (*F*~1,50~ = 14.48, *P *\<* *0.001), and a significant drug--ouabain interaction (*F*~5,50~ = 2.41, *P *\<* *0.05). Post hoc analyses demonstrated that a single, acute i.c.v. injection (5 *μ*L) of 1 mmol/L ouabain caused a significant increase in open field activity (number of squares traversed in 30 min) immediately after injection, compared with an injection of vehicle (aCSF) alone (mean ± SEM: 114.6 ± 14.33 and 60.6 ± 4.30, respectively; *P *\<* *0.01) (Fig.[3](#fig03){ref-type="fig"}). However, no significant effect of ouabain was found in cariprazine- or lithium-treated animals. A significant (*P *\<* *0.01) reduction in ouabain-induced hyperactivity was observed after acute i.p. administration of all doses of cariprazine (mean ± SEM: 0.06 mg/kg, 64.2 ± 3.88; 0.25 mg/kg, 72.7 ± 11.67; 0.50 mg/kg, 40.6 ± 5.32; 1.0 mg/kg, 19.5 ± 8.78) and lithium (40.4 ± 12.78), compared with ouabain injection alone (114.6 ± 14.33) (Fig.[3](#fig03){ref-type="fig"}). The highest cariprazine dose produced significant sedation (72% inhibition for cariprazine 1.0 mg/kg aCSF vs. saline aCSF; *P *\<* *0.05).

![Open field activity immediately after injection with ouabain Acute administration of cariprazine inhibits ICV ouabain-induced motoric hyperactivity in rats. The open field activities were measured immediately after ouabain injection (1 h after cariprazine treatment), or 18 h after lithium treatment. aCSF indicates artificial cerebrospinal fluid (vehicle for ouabain injection); car/*x*, cariprazine/concentration (in mg/kg); Li-18h, lithium treatment, assessed 18 h after injection. ^†^indicates *P *\< 0.05; cariprazine/aCSF versus saline/aCSF ^††^indicates *P *\< 0.01; saline/ouabain versus saline/aCSF \*\*,\*\*\*indicates *P *\< 0.01 and *P *\< 0.001, respectively; cariprazine/ouabain versus saline/ouabain.](prp20003-e00073-f3){#fig03}

To investigate the effects of longer term cariprazine treatment, we administered cariprazine (0.06--1.0 mg/kg) or lithium 1 h before the single-dose administration of ouabain and once daily for 7 days thereafter. A two-factorial ANOVA revealed no significant drug effects, but a significant ouabain effect (*F*~1,52~ = 7.39, *P *\<* *0.01) and drug--ouabain interaction (*F*~5,52~ = 5.30, *P *\<* *0.001). Post hoc analyses showed no significant differences between any two of the aCSF vehicle-treated groups, but a significant effect of ouabain (vs. aCSF vehicle) in the saline-treated group (198.4 ± 19.85 vs. 75.2 ± 20.87, respectively, *P *\<* *0.01) (Fig.[4](#fig04){ref-type="fig"}); there were no significant effects of ouabain (vs. aCSF vehicle) in the cariprazine- or lithium-treated groups. Administration of 1.0 mg/kg cariprazine i.p. for 7 days significantly decreased ouabain-induced hyperactivity (98.60 ± 23.05 vs. 198.4 ± 19.55; *P *\<* *0.05) (Fig.[4](#fig04){ref-type="fig"}). Treatment with 0.06 and 0.5 mg/kg cariprazine for 7 days, as well as 7 days of treatment with lithium, showed decreases in hyperactivity that bordered on significance (111.8 ± 22.94, 110.20 ± 19.18, and 130.1 ± 17.40, respectively; *P *\<* *0.08). Interestingly, in the 7-day dosing studies, there appeared to be a bimodal pattern of decreased hyperactivity, with higher and lower doses of cariprazine being more effective than the 0.25 mg/kg dose.

![Open field activity 7 days after injection with ouabain. Administration of cariprazine for 7 days inhibits ICV ouabain-induced motoric hyperactivity in rats. The open field activities were measured 7 days after a single administration of ouabain. aCSF indicates artificial cerebrospinal fluid (vehicle for ouabain injection); car/*x*, cariprazine/concentration (in mg/kg); Li, lithium treatment (administered daily in food). †indicates *P *\< 0.01; saline/ouabain versus saline/aCSF \*indicates *P *\< 0.05; cariprazine/ouabain versus saline/ouabain.](prp20003-e00073-f4){#fig04}

Discussion
==========

The dopamine D~2~R has been classically shown to mediate its modulatory effects on synaptic transmission *via* signal transduction through G~i/o~-mediated inhibition of cAMP [@b35]. In addition to this G protein-dependent pathway, several lines of evidence suggest that D~2~R can also engage a G protein-independent pathway, inhibiting the Akt/GSK-3 signaling cascade. This mode of signaling is mediated by a molecular complex involving the D~2~R, â-arrestin 2, Akt, and the multimeric protein phosphatase PP2A [@b4].

Various genetic and preclinical studies suggest that Akt and GSK-3 may be associated with the pathophysiology of schizophrenia ([@b17]; [@b25]; [@b37]). In support of this hypothesis, [@b16] have reported decreased Akt1 protein levels and GSK-3*β* phosphorylation in the lymphocytes and postmortem brain of individuals with schizophrenia. Haplotype variants in the Akt1 gene are positively associated with schizophrenia pedigrees ([@b24]; [@b40]), and nonsymptomatic individuals carrying these haplotypes show similar deficits in lymphocyte Akt levels, as well as cognitive deficits associated with executive function [@b43]. In addition, Akt1 deficiency in mice affects neuronal morphology and predisposes them to impaired prefrontal function [@b31], while transgenic overexpression of GSK-3*β* results in hyperactive behavior that models mania [@b39]. Furthermore, several antipsychotics have been shown to affect GSK-3 phosphorylation [@b1], and the mood stabilizer lithium is also believed to inhibit GSK-3 activity, either directly, or by increasing phosphorylation/activation of Akt via destabilization of the D~2~R-mediated complex of *β*-arrestin-2/Akt/PP2A ([@b6]; [@b38]). Hyperactivation of GSK-3 has also been hypothesized to be involved in bipolar disorder [@b32].

In this study, cariprazine and aripiprazole acted as partial agonists for D~2~R/G protein-meditated cAMP production, but very weak agonists at the D~2~R/*β*-arrestin 2 interactions. Both compounds effectively antagonized the ability of the receptor to interact with *β*-arrestin 2. Interestingly, in the BRET-based assay used in our study to monitor D~2~R/*β*-arrestin 2 interactions, both cariprazine and aripiprazole exhibited only marginal agonist activities. However, aripiprazole has been shown to function as a partial agonist for â-arrestin-2 recruitment using assays that amplify the D~2~R/*β*-arrestin 2 signal [@b2]. As depicted in Figure[2B](#fig02){ref-type="fig"} and C a similar situation exists for cariprazine since in the presence of overexpression of the receptor kinase GRK2, the partial agonist activity of cariprazine is significantly enhanced. Interestingly, the potency of antagonism of quinpirole-mediated D~2~R/*β*-arrestin-2 interactions in this study correlated with the clinical efficacy of the three compounds in bipolar disorder, as suggested in a recent meta-analysis (cariprazine = haloperidol \> aripiprazole) [@b45]. If the Akt/GSK-3 signaling pathway is important in some endophenotypes of schizophrenia and bipolar disorder, specifically targeting this pathway may represent a new therapeutic opportunity in both disorders. In addition, the activity of cariprazine at the D~3~R ([@b20]; [@b29]) may enhance its response at the D~2~R [@b5]. The current experiments did not include recombinant D~3~R expression in the model system so any potential D~3~R-mediated effects of cariprazine on the Akt/GSK-3 signaling would not be seen in these assays.

In our animal behavioral studies, acute administration of cariprazine attenuated ouabain-induced hyper-locomotor activity at all doses tested. Longer term administration of cariprazine at all doses except 0.25 mg/kg prevented ouabain-induced hyperactivity reaching statistical significance at the 1.0 mg/kg dosing level. The effects of cariprazine in both the acute and the 7-day studies were similar to the effects seen in animals treated with lithium. The acute administration of 1 mg/kg cariprazine alone significantly decreased open field activity (Fig.[3](#fig03){ref-type="fig"}), suggesting a possible sedating effect of acute administration at this dose.

Intracerebroventricular ouabain injection is a well-characterized model of mania that adequately fulfills multiple criteria required of an animal model [@b21]. Ouabain increases dopamine levels in the synapse ([@b9]; [@b8]), and ouabain-induced hyperactivity is reduced with lithium and other antimanic agents (such as carbamazepine and haloperidol) [@b21]. Ouabain can also alter the phosphorylation state of Akt in some cell lines ([@b26],[@b27]; [@b41]), as well as in vivo in rats [@b47], although it should be noted that the effects of ouabain are actually contrary to what would be expected according to the Akt/GSK-3 model. According to this model, symptoms of mania [@b32] and schizophrenia [@b30] are caused by an overstimulation of the D~2~R, leading to the inactivation of Akt through dephosphorylation, followed by a dephosphorylation/hyperactivation of GSK-3 [@b4]. In the ouabain model of mania, however, i.c.v. injection of ouabain induces a dose-dependent increase in the immunoreactivity of phosphorylated Akt, and also leads to increased phosphorylation of downstream proteins GSK-3â, endothelial nitric oxide synthase, and Forkhead box protein O1 [@b47]. Despite this discrepancy in the direction of Akt phosphorylation, it is possible that perturbations in the Akt/GSK-3 system in general may underlie the symptoms of mania and schizophrenia, in ways that are more complex than the current models predict.

While the ouabain paradigm is associated with several behavioral and neurobiological facets of mania, it primarily models the hyperactivity symptoms associated with mania. Bipolar mania, though, is a complex and multidimensional disease with a spectrum of symptoms that cannot be accurately evaluated in any single animal model [@b46] Investigation of cariprazine in other behavioral models that represent additional mania symptom domains including sleep deprivation, aggression, reward-seeking behavior, and cognitive impairment is warranted [@b46].

Phase III clinical trials of cariprazine have now been successfully completed in patients with schizophrenia and in patients with bipolar disorder [@b11],[@b12] and the results from a recent meta-analysis of antimanic treatments suggest that cariprazine demonstrates robust clinical efficacy in patients with acute mania associated with bipolar disorder [@b45]. The effects of cariprazine on Akt/GSK-3 signaling may play a role in its antimanic efficacy.
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aCSF

:   artificial cerebrospinal fluid

Akt

:   protein kinase B

ANOVA

:   analysis of variance

BRET

:   bioluminescence resonance energy transfer

D~2~R

:   dopamine 2 receptor

D~3~R

:   dopamine 3 receptor

EYFP

:   enhanced yellow fluorescent protein

FBS

:   fetal bovine serum

GSK-3

:   glycogen synthase kinase-3

HBSS

:   Hank\'s Balanced Salt Solution

HEK

:   human embryonic kidney

mD~2L~R

:   mouse dopamine receptor D~2~-long form

m*β*-arrestin-2

:   mouse *β*-arrestin-2

PBS

:   Phosphate Buffer Saline

PP2A

:   protein phosphatase 2A

RLuc

:   *Renilla* luciferase

[^1]: **Funding Information** This study was funded by Forest Laboratories, Inc., and Gedeon Richter, Plc.
